Clinical Trial Update: Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating belatacept as a replacement for calcineurin inhibitors 3 to 12 months after kidney transplantation in patients with early graf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Belatacept (Nulojix) (belatacept)

Snippet

Sponsor: Nantes University Hospital | Conditions: Chronic Kidney Failure | Phase 3 | Status: RECRUITING